Company Overview - Dongxiao Biotechnology Co., Ltd. announced plans to publicly issue up to 28,207,567 shares to unspecified qualified investors and list on the Beijing Stock Exchange [1] - The public shareholders will hold no less than 25% of the total share capital after the issuance [1] - The company may utilize an overallotment option, allowing for an additional issuance of up to 15% of the public offering shares [1] Fundraising Purpose - The funds raised will be allocated to projects including functional sugar alcohol industrial upgrade, high-value amino acid intelligent construction, innovation R&D base, and working capital supplementation [1] Industry Insights - The global amino acid market is expected to grow at a compound annual growth rate (CAGR) of 4.7% from 2022 to 2027, reaching a production scale of 13.8 million tons by 2027 [2] - In 2023, China's share of global feed amino acid production (including lysine, methionine, threonine, and tryptophan) is projected to increase to 70.4% [2] - The Chinese plant-based cream market is estimated to reach approximately 9.008 billion yuan in 2023, with a year-on-year growth of about 9.99% [2] Financial Performance - The company reported a revenue of 7.84 billion yuan and a net profit of 578 million yuan for the year 2024, reflecting a year-on-year increase of 93.98% [2]
东晓生物：以多元化玉米精深加工为主业的重点龙头企业
Xin Lang Cai Jing·2026-01-21 01:00